Physician profile
David R Hadlock
NPI 1629101928
$1,361.26
in general payments reported to CMS, 2019-2025
11 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Addiction Medicine (Family Medicine) provider received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.87 · 2021: $265 · 2022: $398 · 2023: $329 · 2024: $68.20 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,171.54 | 2019-2025 | |
| Lundbeck LLC | $45.71 | 2023 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.48 | 2023 | Relistor |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.91 | 2025 | Caplyta |
| Allergan, INC. | $17.21 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.87 | 2022 | |
| Mdd US Operations, LLC | $14.12 | 2019 | |
| Medtronic, INC. | $13.94 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.46 | 2019 | |
| Mayne Pharma Commercial LLC | $6.02 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hadlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.